Do policies to lower U.S. drug prices reduce pharmaceutical research investment?
Core argument: The authors calculate that a single international drug price across the highest-income OECD countries, holding total pharmaceutical firm profits fixed, would cut U.S. prices by half while raising every other country's prices by 28% to 300%.
As long as the vast majority of the funds for research keep being supplied by firms, an increase in pharmaceutical research likely requires increased private incentives to do that research.Our calculations indicate that currently proposed U.S. policies to reduce pharmaceutical prices, though particularly beneficial for low-income and elderly populations, could dramatically reducefirms’ investment in highly welfare-improving R&D. The U.S. subsidizes the worldwide pharmaceutical market. One reason is U.S. prices are higher than elsewhere. If each drug had asingle international price across the highest-income OECD countries, and total pharmaceutical firm profits were held fixed, then U.S. prices would fall by half and every other country’s prices would increase (by 28% to 300%). International prices would maintain firms’ R&D incentives and more equitably share the costs of pharmaceutical research.


